At this year Mt Hood diabetes challenge conference we finally got the chance to award Pierre Johansen, Senior Health Economist at Novo Nordisk with a prize for this paper https://t.co/MmnnXBLYkE We plan to award a 2nd Transparency Prize at our next meeting
RT @ApplHealthEcon: We're very happy the first winner of this #modelling #transparency prize published in PharmacoEconomics Open! We stri…
RT @ApplHealthEcon: We're very happy the first winner of this #modelling #transparency prize published in PharmacoEconomics Open! We stri…
RT @pmc868: Pleased to announce the winner of the Mt Hood Modelling Transparency Prize is Pierre Johansen for his paper Cost Effectiveness…
The Mt Hood Diabetes Challenge Transparency offer prizes to those who aim to improve #transparency in #modelling. Congratulations to Pierre Johansen for his paper "Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide." Read more: h
We're very happy the first winner of this #modelling #transparency prize published in PharmacoEconomics Open! We strive to publish clear and complete reports of economic models and strongly encourage model sharing, and it's great to see authors recognize
RT @pmc868: Pleased to announce the winner of the Mt Hood Modelling Transparency Prize is Pierre Johansen for his paper Cost Effectiveness…
RT @pmc868: Pleased to announce the winner of the Mt Hood Modelling Transparency Prize is Pierre Johansen for his paper Cost Effectiveness…
RT @pmc868: Pleased to announce the winner of the Mt Hood Modelling Transparency Prize is Pierre Johansen for his paper Cost Effectiveness…
RT @pmc868: Pleased to announce the winner of the Mt Hood Modelling Transparency Prize is Pierre Johansen for his paper Cost Effectiveness…
Pleased to announce the winner of the Mt Hood Modelling Transparency Prize is Pierre Johansen for his paper Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide. More info on guidelines & prize: https://t.co/5gWyVo0ogy Paper:
#HealthEconJA Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada https://t.co/P6BvqUl2bO